Prestige BioPharma프레스티지바이오파마

Prestige BioPharma reported positive net income in FY2025 on a sharp jump in revenue, but it still runs large operating losses and its shares are down sharply over the past year.

The company is a biopharma firm developing antibody drugs and selling biosimilars such as TUZNUE through regional partners, and it also offers contract manufacturing. In FY2025 revenue rose to ₩10.2B from ₩0.5B the year before, yet operating losses were about ₩48B and the reported net profit of ₩15.9B is not explained in the data. The share price closed at ₩5,050 on 27 October 2026, roughly 62% lower over one year.

What stands out

• FY2025 revenue was ₩10.2B, up about 1,875% year on year, but operating income was a loss of ₩48.0B (operating margin -470%).
• Net income was positive at ₩15.9B in FY2025, while operating results were negative; the data does not explain the gap.
• Cash of ₩85.1B is below borrowings of ₩105.1B, and free cash flow was -₩66.2B.
• Valuation metrics are extremely high (P/E about 19,088, P/B about 1,002) and the company pays no dividend; the data includes no fair value estimate.
• Foreign investors held 63.7% of shares, unchanged over 60 days, while retail investors were net sellers over the last 20 days.

What to watch

• The next annual results and whether operating losses narrow relative to revenue.
• Filings on the shareholders' meeting, auditor change and the amended annual report, plus any new sales or supply contracts.
• Whether the company can keep reducing its net debt position given cash below borrowings and negative free cash flow.